Chardan Capital Says to Buy Spark Therapeutics (ONCE) Peers Following SPK-RPE65 Results (AAVL) (VBLT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
Roth Capital Raises Price Target on Spark Therapeutics (ONCE) to $90 Following Top-Line Results
October 5, 2015 11:03 AM EDTRoth Capital reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE), and raised the price target to $90.00 (from $71.00), following the announced top-line results for the Phase 3 trial of SPKRPE65. The reported study represents the first successful controlled gene therapy trial. Spark... More
Spark Therapeutics (ONCE) Announces SPK-RPE65 Phase 3 Met Primary Endpoint
October 5, 2015 6:23 AM EDTSpark Therapeutics (NASDAQ: ONCE) announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs).
The pivotal trial met its primary endpoint (p = 0.001), demonstrating improvement of functional vision in the intervention group compared to the control group, as measured by the change in bilateral mobility testing between baseline and one year.
There were no serious adverse events related to SPK-RPE65 or deleterious immune responses observed in the trial.... More
